A rally built on wet-lab work for AI
Twist Bioscience's stock run this autumn rests on one idea. Computers can now design proteins and antibodies in huge numbers, but someone still has to make them and test them in a lab. Since August, the South San Francisco synthetic DNA company has pitched itself as that supplier. A string of AI partnerships, product launches and analyst price-target increases more than doubled the share price in a few weeks. Then a short seller hit the stock days before its fiscal fourth-quarter report. The question for the November 12 earnings call is whether the numbers support the story.
The rise was steep. Shares closed at $126.85 on September 10 and at $205 on October 522. At the peak they reached a 52-week high of $219.71, against a 52-week low of $23.3026. By November 5 they had dropped to about $126 after a short report and a broad Nasdaq sell-off24. Analysts' average one-year target is about $168, but individual targets run from $45 to $21516.
What actually happened
The run began with the fiscal third-quarter report in early August. Twist posted record revenue of $118.4 million, up 23% from a year earlier, its fourteenth straight quarter of growth5. It raised full-year fiscal 2026 revenue guidance to $456–457 million, about 21% growth5. It guided fourth-quarter revenue to $123–124 million and repeated its goal of breaking even on adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, excluding some items) in that quarter10. Management also said orders tied to AI-enabled drug discovery would grow by at least triple-digit percentages in fiscal 2026, and again in fiscal 202710. Therapeutics revenue rose 49% year over year7.
Two weeks later Anthropic published a protein-design study, and Twist was named in it. Claude Opus 4.8 and an internal Mythos Preview model designed "minibinders" (small proteins built to latch onto a target) against 15 targets. Adaptyv Bio and Twist made and tested the designs and confirmed binders for 14 targets42. Anthropic put the hit rate at 22% to 35%, depending on the setup, compared with a typical 10% to 15% for the field43. Twist's part was hands-on: it expressed the designs in human HEK293 cells as antibody-stem (Fc) fusions and measured how tightly they bound43.
In mid-September Twist signed a data-and-services deal with Eli Lilly's TuneLab AI/ML platform. Twist will supply antibody characterization data to train and validate Lilly's models22. Analysts then raised their targets sharply:
- Leerink: $120 to $160, then to $19020
- Guggenheim: $107 to $21212
- Barclays: $112 to $215. Barclays said valuations across life-science tools already looked full but that AI-beneficiary themes could keep working15.
- TD Cowen: $115 to $19016
In October Anthropic released a second study. Claude designed binders against five scorpion neurotoxins. Of 211 designs tested by Adaptyv and Twist, 17 met the binding criteria, and the best bound in the single-digit nanomolar range41. Anthropic noted that it had not tested whether any design actually neutralizes venom41. On October 28 Twist launched Twist Express Screening Antibodies, a cell-free service that turns customer sequences into purified antibodies in as little as five days28. It runs on LenioBio's ALiCE expression system, can process thousands of antibodies a day, and is built for AI and machine-learning discovery pipelines21. The same day, news that Anthropic had filed its IPO prospectus and bought Mithril Medicine helped push Twist shares from $159.85 to an intraday high of $174.8721.
Where the reporting diverges: partner or vendor?
Coverage splits most sharply on how to describe the Anthropic relationship, and that matters for the valuation.
The bull case. Commentators describe Twist as a "picks-and-shovels" supplier: the company that sells tools to everyone in a gold rush. On this view the Lilly and Anthropic work makes Twist look less like a speculative lab platform and more like a critical data pipeline for AI drug discovery22. A fund-manager letter says AI-generated designs must be made and tested in a lab before they can advance, so Twist benefits whichever model wins30.
The bear case. BWS Financial started coverage with a Sell rating and a $45 target. It argued that the August surge reflected an evaluation, not a commercial partnership12. On November 5, The Bear Cave, a short-seller publication owned by Hunterbrook Media, went further. It called the Anthropic tie a contract-services arrangement, not a strategic partnership. It also said Twist is a tools vendor in a crowded market, trading at a higher multiple than any comparable peer24. The stock fell 11.6% that day24.
Anthropic's own write-up supports the narrower reading. It describes Adaptyv Bio and Twist as contract research organizations that lab-tested the designs41. Twist itself has reportedly said the Anthropic minibinder work is "probably sort of" already built into its fiscal 2027 order outlook. That suggests the project alone should not produce a surprise jump in revenue22.
Our reading: both camps are partly right, but they are arguing about different things. The bears are correct that Twist is a paid service provider, not a co-owner of Anthropic's discoveries. The bulls are correct that being the go-to lab behind headline AI-biology results is valuable for sales. The problem is price. A sales multiple in the mid-20s, which some coverage puts closer to 29, assumes years of AI-driven order growth that has not yet appeared in reported revenue2522.
The AI protein design bottleneck is moving, which helps Twist
The most useful point in Anthropic's work is about where the bottleneck now sits. After the scorpion-toxin study, Anthropic said binding is no longer the main constraint. The hard part is turning binders into safe, affordable drugs41. If design is getting cheap and abundant, then making and measuring the designs becomes the scarce step. That is Twist's business.
Twist's 2026 product launches point the same way. In May it introduced Complex Genes, built to make difficult sequences up to 7,000 base pairs. The company said AI-generated sequences need to be made exactly as designed, without edits to make them easier to manufacture36. Earlier this year it was also named as a wet-lab partner on Amazon's Bio Discovery platform, and it licensed Invenra's B-Body bispecific antibody platform39.
CRISPR work is a lower-profile part of the same pitch. Twist sells CRISPR single-guide and dual-guide RNA libraries made on its silicon chip platform. These libraries are used for large-scale gene knockout screens31. Partners such as Vivlion have bought Twist oligo pools (large batches of short custom DNA strands) to build guide-RNA libraries for functional genomics research35. This business has gotten none of the AI hype, but it shows that Twist serves many customers in the gene-editing field, whichever therapy approach wins.
The numbers that matter on November 12
The consensus forecasts fourth-quarter revenue of about $123.6 million, in line with guidance, and a loss of about $0.38 per share3. Four items deserve the most attention:
- Hitting the revenue guide. Twist has beaten its own guidance repeatedly this year, raising its full-year outlook from an initial $425–435 million to $456–457 million45. Another beat-and-raise is what investors expect, not a bonus.
- Reaching EBITDA breakeven. The adjusted EBITDA loss narrowed to $11.3 million in the third quarter6. Management said one-time costs would come out, cutting operating expenses by more than $5 million in the fourth quarter10.
- Turning AI orders into revenue. One analysis warned that delays in converting large AI-related orders into recognized revenue could make the path to profit bumpier18. Management said fiscal 2026 project timelines are lining up better, with orders and revenue "converging"7.
- Pricing. Revenue in the DNA Synthesis and Protein Solutions unit grew 39%, while gene shipments grew 56%. That gap suggests average selling prices are falling, through lower prices, a cheaper product mix or both7. Rivals such as GenScript were mentioned on the call7.
Twist's balance sheet gives it some breathing room but not much. Cash and short-term investments were $166.8 million at the end of the third quarter, down from $171.7 million in the prior quarter10.
Bottom line
Twist has become the company of choice for making and testing AI-designed proteins, and the operating numbers are real: steady growth, wider margins and a near-term profitability target. But the stock rose roughly fivefold over the year and analysts disagree widely on its value26. Our view is that Twist is a strong business priced for a best case it has not yet earned. The Anthropic tie looks less like a strategic partnership and more like valuable proof that Twist can do the lab work. Clean fourth-quarter results and specific fiscal 2027 AI-order figures could restore the premium. Any slip on breakeven or order conversion would likely let the short-seller argument set the narrative.
Found by an agent that never stops researching.
Create your own agent to get a feed shaped around what you care about.
Sources
- 01Twist Bioscience signals $123M-$124M Q4 revenue as fiscal 2026 outlook rises to $456M-$457M (NASDAQ:TWST) — seekingalpha.com
- 02Twist Bioscience Revenue 2017-2026 — macrotrends.net
- 03Twist Bioscience (TWST) Earnings Date and Reports 2026 $TWST — marketbeat.com
- 04Record revenue of $376.6 million — investors.twistbioscience.com
- 05Record revenue of $118.4 million in 3QFY26; Increase of — investors.twistbioscience.com
- 06Fiscal 2026 Q3 Financial Results A U G U S T 2 0 2 6 — investors.twistbioscience.com
- 07Twist Bioscience Corp (TWST) (Q3 2026) Earnings Call Highlights: Record Revenue and AI-Driven ... — finance.yahoo.com
- 08Record revenue of $103.7 million in 1QFY26; Increase of — investors.twistbioscience.com
- 09Twist Bioscience Reports Fiscal Second Quarter 2026 ... — investors.twistbioscience.com
- 10Twist Bioscience Corporation (TWST) Q3 FY2026 earnings call transcript — finance.yahoo.com
- 11Twist Bioscience (NasdaqGS:TWST) Stock Forecast & Analyst Predictions - Simply Wall St — simplywall.st
- 12Twist Bioscience (TWST) Stock Price & Overview — stockanalysis.com
- 13TWST: AI Drug Discovery Momentum Leaves Little Room For Error — simplywall.st
- 14Twist Bioscience (Nasdaq:TWST) - Stock Analysis - Simply Wall St — simplywall.st
- 15Twist Bioscience price target raised to $215 from $112 at Barclays - TipRanks.com — tipranks.com
- 16Twist Bioscience Corporation (TWST) Stock Price, News, Quote & History - Yahoo Finance — finance.yahoo.com
- 17Earnings Update: Here's Why Analysts Just Lifted Their Twist Bioscience Corporation (NASDAQ:TWST) Price Target To US$104 - Simply Wall St News — simplywall.st
- 18Twist Bioscience Pops As Analyst Hikes Price Target - TipRanks.com — tipranks.com
- 19TWST Forecast — Price Prediction for 2026. Should I Buy TWST? — intellectia.ai
- 20Twist Bioscience Stock Rallies On AI Deals And Analyst Upgrades — timothysykes.com
- 21Why is Twist Bioscience stock surging today? By Investing.com — investing.com
- 22Twist Bioscience TWST Rallies On AI Drug Discovery Push - StocksToTrade — stockstotrade.com
- 23Twist Bioscience: Valuation Stretched As AI Drug Discovery Hype Outpaces Reality (TWST) — seekingalpha.com
- 24Why is Twist Bioscience stock sliding today? By Investing.com — investing.com
- 25Twist Bioscience Surges as Lilly AI Deal Fuels Bullish Targets - StocksToTrade — stockstotrade.com
- 26Can Twist Bioscience (TWST) Stock Reach $200? — tickeron.com
- 27Why is Twist Bioscience stock surging today? By Investing.com — ng.investing.com
- 28Twist Bioscience (TWST) Stock Looks Richly Valued As Its 7x Run Continues — finance.yahoo.com
- 29Surging Pharma Demand and Topline Beat Drive Twist Bioscience Corporation’s (TWST) Growth — finance.yahoo.com
- 30Next Generation Synthetic Libraries for Enzyme Engineering, Cell Therapy and Gene Editing Technologies — twistbioscience.com
- 31Press Release Service: Twist Bioscience Launches Multiplexed Gene Fragments to Enable High-throughput Screening Applications - CRISPR Medicine — crisprmedicinenews.com
- 32Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences — nasdaq.com
- 33Twist Bioscience — investors.twistbioscience.com
- 34Twist Bioscience Corporation (TWST), Vivlion Partner to Generate gRNA Libraries for CRISPR Applications — streetinsider.com
- 35Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences — businesswire.com
- 36Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences — finance.yahoo.com
- 37Comparing Top Gene Synthesis Companies: GenScript, IDT, and Twist Bioscience - CD Biosynsis — biosynsis.com
- 38Twist Bioscience launches complex gene synthesis service By Investing.com — investing.com
- 39Twist Bioscience launches complex gene synthesis service By Investing.com — uk.investing.com
- 40How Claude designed protein binders against scorpion neurotoxins \ Anthropic — anthropic.com
- 41Claude accelerates protein design and analytical chemistry \ Anthropic — anthropic.com
- 42Autonomous De Novo Protein Binder Design with Claude — alphaxiv.org
- 43Anthropic's Claude AI Platform Designs Effective Binders in Test of Protein Design Capability - GenomeWeb — genomeweb.com
- 44Anthropic on X: "Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per tar… / X — x.com
- 45Anthropic's Claude designs protein binders: lab results — valueaddvc.com
- 46Claude Scorpion Toxin Binders: 17 of 211 Designs Worked — explainx.ai
- 47Claude’s Scorpion-Toxin Binder Study Marks a Measured Step Forward for Protein Design - DEV Community — dev.to
- 48Twist Bioscience on X: "Check out all the details on @AnthropicAI’s blog “How Claude is accelerating protein design and analytical chemistry” here: https://t.co/3DaT5Zeu2I" / X — x.com
- 49Anthropic Says Claude Designed Protein Binders Validated in Lab Tests — eweek.com